Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Risk information for Alzheimer disease (AD) may be communicated through susceptibility gene disclosure, even though this is not currently in clinical use. The REVEAL Study is the first randomized clinical trial of risk assessment for AD with apolipoprotein E (APOE) genotype and numerical risk estimate disclosure. We examined whether APOE genotype and numerical risk disclosure to asymptomatic individuals at high risk for AD alters health behaviors. One hundred sixty-two participants were randomized to either intervention (APOE disclosure) or control (no genotype disclosure) groups. Subjects in both groups received numerical lifetime risk estimates of future AD development based on sex and family history of AD. The intervention group received their APOE genotype. Subjects were informed that no proven preventive measures for AD existed and given an information sheet on preventative therapies under investigation. Participants who learned they were epsilon 4 positive were significantly more likely than epsilon 4 negative participants to report AD-specific health behavior change 1 year after disclosure (adjusted odds ratio: 2.73; 95% confidence interval: 1.14, 6.54; P=0.02). Post hoc analyses revealed similar significant associations between numerical lifetime risk estimates and self-report of AD-specific health behavior change. Despite lack of preventive measures for AD, knowledge of APOE genotype, numerical lifetime risk, or both, influences health behavior.
Chao
Serena
S
Department of Medicine (Geriatrics Section) Boston University School of Medicine, Boston, MA 02118, USA.
Roberts
J Scott
JS
Marteau
Theresa M
TM
Silliman
Rebecca
R
Cupples
L Adrienne
LA
Green
Robert C
RC
D000544:Alzheimer Disease / Q000235:genetics* / Q000517:prevention & control*; D001057:Apolipoproteins E / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000523:psychology*; D005820:Genetic Testing / Q000523:psychology; D005838:Genotype; D015438:Health Behavior; D006801:Humans; D018570:Risk Assessment
D001057:Apolipoproteins E